Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Express Scripts
Healthtrust
Argus Health
Boehringer Ingelheim
Cantor Fitzgerald

Generated: August 18, 2019

DrugPatentWatch Database Preview

Claims for Patent: 8,148,401

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,148,401
Title:Benzimidazole derivatives
Abstract: The present invention relates to a compound of the Formula I ##STR00001## or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3A, R.sup.3B, R.sup.4, R.sup.5, X, m, and n are as defined herein. Such novel benzamidazole derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
Inventor(s): Munchhof; Michael J. (Salem, CT), Reiter; Lawrence A. (Mystic, CT), La Greca; Susan D. (Old Lyme, CT), Jones; Christopher S. (Gales Ferry, CT), Li; Qifang (Stonington, CT)
Assignee: Pfizer Inc. (New York, NY)
Application Number:12/142,119
Patent Claims: 1. A compound of Formula II(a), ##STR00198## wherein: each R.sup.1 is independently halo, (C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)alkoxy, --CF.sub.3, --CN, or --NR.sup.16R.sup.17; R.sup.2 is hydrogen or (C.sub.1-C.sub.6)alkyl; R.sup.3B is hydrogen, (C.sub.1-C.sub.6)alkyl, --(CH.sub.2).sub.t(C.sub.6-C.sub.12)aryl, or --(CH.sub.2).sub.t(C.sub.3-C.sub.12)carbocyclyl; R.sup.4 is hydrogen or (C.sub.1-C.sub.6)alkyl; R.sup.10 is --(CH.sub.2).sub.t(C.sub.6-C.sub.12)aryl or --(CH.sub.2).sub.t(4 to 14 membered heterocyclyl), wherein each of said (C.sub.6-C.sub.12)aryl and (4 to 14 membered heterocyclyl) is optionally substituted with from 1 to 5 substituents each of which is independently selected from (C.sub.1-C.sub.6)alkyl, --CN, halo, --CF.sub.3, --OCF.sub.3, --NR.sup.16R.sup.17, (C.sub.1-C.sub.6)alkoxy, --NO.sub.2, --(CH.sub.2).sub.t(C.sub.6-C.sub.12)aryl, --C(O)(C.sub.1-C.sub.6 alkyl), --C(O)CF.sub.3, azido, (4 to 12 membered heterocyclyl), and --S((C.sub.1-C.sub.6)alkyl); each R.sup.16 and R.sup.17 is independently selected from hydrogen and (C.sub.1-C.sub.6)alkyl; n is 0, 1, 2, 3, or 4; and each t is independently 0, 1, or 2; or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1, wherein: each R.sup.1 is independently F, Cl, Br, --CH.sub.3, --OCH.sub.3, --CF.sub.3, --CN, or --NR.sup.16R.sup.17; R.sup.2 is hydrogen; R.sup.3B is hydrogen, --CH.sub.3, --CH.sub.2CH.sub.3, --CH.sub.2CH.sub.2CH.sub.3, --CH(CH.sub.3).sub.2, --CH.sub.2CH.sub.2CH.sub.2CH.sub.3, --CH.sub.2CH(CH.sub.3).sub.2, or --CH.sub.2(phenyl); R.sup.4 is hydrogen; and R.sup.10 is phenyl, pyridyl, or 2,3-dihydro-1,4-benzodioxinyl, wherein each of said phenyl, pyridyl, and 2,3-dihydro-1,4-benzodioxinyl is optionally substituted with from 1 to 5 substituents each of which is independently selected from (C.sub.1-C.sub.6)alkyl, --CN, halo, --CF.sub.3, --OCF.sub.3, --NR.sup.16R.sup.17, (C.sub.1-C.sub.6)alkoxy, --NO.sub.2, --(CH.sub.2).sub.t(C.sub.6-C.sub.12)aryl, --C(O)(C.sub.1-C.sub.6 alkyl), --C(O)CF.sub.3, azido, (4 to 12 membered heterocyclyl), and --S((C.sub.1-C.sub.6)alkyl); or a pharmaceutically acceptable salt thereof.

3. A compound according to claim 2, wherein: each R.sup.1 is independently F, Cl, --CH.sub.3, --OCH.sub.3, --CF.sub.3, --CN, or --N(CH.sub.3).sub.2; R.sup.3B is --CH.sub.3; and R.sup.10 is phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, or 2,3-dihydro-1,4-benzodioxin-6-yl, wherein each of said phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, and 2,3-dihydro-1,4-benzodioxin-6-yl is optionally substituted with from 1 to 5 substituents each of which is independently selected from (C.sub.1-C.sub.6)alkyl, --CN, halo, --CF.sub.3, --OCF.sub.3, --NR.sup.16R.sup.17, (C.sub.1-C.sub.6)alkoxy, --NO.sub.2, --(CH.sub.2).sub.t(C.sub.6-C.sub.12)aryl, --C(O)(C.sub.1-C.sub.6 alkyl), --C(O)CF.sub.3, azido, (4 to 12 membered heterocyclyl), and --S((C.sub.1-C.sub.6)alkyl); or a pharmaceutically acceptable salt thereof.

4. A compound according to claim 3, wherein R.sup.10 is phenyl, 3-pyridyl, or 2,3-dihydro-1,4-benzodioxin-6-yl, wherein each of said phenyl, 3-pyridyl, and 2,3-dihydro-1,4-benzodioxin-6-yl is optionally substituted with from 1 to 5 substituents each of which is independently selected from (C.sub.1-C.sub.6)alkyl, --CN, halo, --CF.sub.3, --OCF.sub.3, --NR.sup.16R.sup.17, (C.sub.1-C.sub.6)alkoxy, --NO.sub.2, --(CH.sub.2).sub.t(C.sub.6-C.sub.12)aryl, --C(O)(C.sub.1-C.sub.6 alkyl), --C(O)CF.sub.3, azido, (4 to 12 membered heterocyclyl), and --S((C.sub.1-C.sub.6)alkyl); or a pharmaceutically acceptable salt thereof.

5. A compound according to claim 4, wherein R.sup.10 is phenyl optionally substituted with from 1 to 5 substituents each of which is independently selected from (C.sub.1-C.sub.6)alkyl, --CN, halo, --CF.sub.3, --OCF.sub.3, --NR.sup.16R.sup.17, (C.sub.1-C.sub.6)alkoxy, --NO.sub.2, --(CH.sub.2).sub.t(C.sub.6-C.sub.12)aryl, --C(O)(C.sub.1-C.sub.6 alkyl), --C(O)CF.sub.3, azido, (4 to 12 membered heterocyclyl), and --S((C.sub.1-C.sub.6)alkyl); or a pharmaceutically acceptable salt thereof.

6. A compound according to claim 5, wherein R.sup.10 is phenyl optionally substituted with from 1 to 5 substituents each of which is independently selected from --CH.sub.3, --CN, --F, --Cl, --Br, --CF.sub.3, --OCF.sub.3, --NR.sup.16R.sup.17, --OCH.sub.3, and --NO.sub.2; or a pharmaceutically acceptable salt thereof.

7. A compound of Formula III(a), ##STR00199## wherein: each R.sup.1 is independently halo, (C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)alkoxy, --CF.sub.3, --CN, or --NR.sup.16R.sup.17; R.sup.2 is hydrogen or (C.sub.1-C.sub.6)alkyl; R.sup.3B is hydrogen, (C.sub.1-C.sub.6)alkyl, --(CH.sub.2).sub.t(C.sub.6-C.sub.12)aryl, or --(CH.sub.2).sub.t(C.sub.3-C.sub.12)carbocyclyl; R.sup.4 is hydrogen or (C.sub.1-C.sub.6)alkyl; R.sup.11 is --(CH.sub.2).sub.t(C.sub.6-C.sub.12)aryl or --(CH.sub.2).sub.t(4 to 14 membered heterocyclyl), wherein each of said (C.sub.6-C.sub.12)aryl and (4 to 14 membered heterocyclyl) is optionally substituted with from 1 to 5 substituents each of which is independently selected from (C.sub.1-C.sub.6)alkyl, --CN, halo, --CF.sub.3, --OCF.sub.3, --NR.sup.16R.sup.17, (C.sub.1-C.sub.6)alkoxy, --NO.sub.2, --(CH.sub.2).sub.t(C.sub.6-C.sub.12)aryl, --C(O)(C.sub.1-C.sub.6 alkyl), --C(O)CF.sub.3, azido, (4 to 12 membered heterocyclyl), and --S((C.sub.1-C.sub.6)alkyl); each R.sup.16 and R.sup.17 is independently selected from hydrogen and (C.sub.1-C.sub.6)alkyl; n is 0, 1, 2, 3, or 4; and each t is independently 0, 1, or 2; or a pharmaceutically acceptable salt thereof.

8. A compound of Formula IV(a) ##STR00200## wherein: each R.sup.1 is independently halo, (C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)alkoxy, --CF.sub.3, --CN, or --NR.sup.16R.sup.17; R.sup.2 is hydrogen or (C.sub.1-C.sub.6)alkyl; R.sup.3B is hydrogen, (C.sub.1-C.sub.6)alkyl, --(CH.sub.2).sub.t(C.sub.6-C.sub.12)aryl, or --(CH.sub.2).sub.t(C.sub.3-C.sub.12)carbocyclyl; R.sup.4 is hydrogen or (C.sub.1-C.sub.6)alkyl; each R.sup.12 is independently selected from --(CH.sub.2).sub.t(C.sub.6-C.sub.12)aryl, --(CH.sub.2).sub.t(4 to 14 membered heterocyclyl), (C.sub.1-C.sub.6)alkyl, --CN, halo, --CF.sub.3, --OCF.sub.3, --NR.sup.16R.sup.17, (C.sub.1-C.sub.6)alkoxy, --NO.sub.2, --(CH.sub.2).sub.t(C.sub.6-C.sub.12)aryl, --C(O)(C.sub.1-C.sub.6 alkyl), --C(O)CF.sub.3, azido, (4 to 12 membered heterocyclyl), and --S((C.sub.1-C.sub.6)alkyl); each R.sup.16 and R.sup.17 is independently selected from hydrogen and (C.sub.1-C.sub.6)alkyl; n is 0, 1, 2, 3, or 4; each t is independently 0, 1, or 2; and z is 0, 1, 2, 3, 4, or 5; or a pharmaceutically acceptable salt thereof.

9. A compound according to claim 8, wherein: R.sup.2 is hydrogen; R.sup.3B is --CH.sub.3; R.sup.4 is hydrogen; and each R.sup.12 is independently selected from --CN, --F, --Cl, --Br, --CF.sub.3, --OCF.sub.3, --NR.sup.16R.sup.17, --OCH.sub.3, and --NO.sub.2; or a pharmaceutically acceptable salt thereof.

10. A compound according to claim 9, wherein: each R.sup.1 is independently halo, --CH.sub.3, --OCH.sub.3, --CF.sub.3, --CN, or --N(CH.sub.3).sub.2; R.sup.12 is --CN, --F, --Cl, --Br, --CF.sub.3, --OCF.sub.3, --OCH.sub.3, or --NO.sub.2; and z is 1; or a pharmaceutically acceptable salt thereof.

11. A compound according to claim 10, wherein: R.sup.12 is --CN, --F, --Cl, --Br, or --CF.sub.3; and n is 0; or a pharmaceutically acceptable salt thereof.

12. A compound according to claim 11, wherein R.sup.12 is --CN, or a pharmaceutically acceptable salt thereof.

13. A compound selected from: 1-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-3-(4-cyanophe- nyl)urea; 1-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-3-(4- -chlorophenyl)urea; 1-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-3-(6-fluoropy- ridin-3-yl)urea; N-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]chromane-6-car- boxamide; N-[(2R,4R)-2-(6-chloro-1H-benzimidazol-2-yl)-1-methylpiperidin-4- -yl]-2,3-dihydro-1,4-benzodioxine-6-carboxamide; 1-{(2R,4R)-1-methyl-2-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]piperidin- -4-yl}-3-[6-(trifluoromethyl)pyridin-3-yl]urea; 1-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-3-(4-methoxyp- henyl)urea; N-[(2R,4R)-2-(6-methoxy-1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-2,3- -dihydro-1,4-benzodioxine-6-carboxamide; 1-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-isobutylpiperidin-4-yl]-3-(4-cyanop- henyl)urea; and 1-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-3-(6-fluoro-5- -methylpyridin-3-yl)urea; or a pharmaceutically acceptable salt thereof.

14. A compound which is ##STR00201## or a pharmaceutically acceptable salt thereof.

15. A compound which is ##STR00202## or a pharmaceutically acceptable salt thereof.

16. A compound which is ##STR00203## or a pharmaceutically acceptable salt thereof.

17. A pharmaceutical composition, comprising an effective amount of at least one compound according to claim 1, and a pharmaceutically acceptable carrier.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Queensland Health
McKinsey
Cipla
Deloitte
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.